|
Brian Atwood co-founded Versant Ventures after spending four years at Brentwood Venture Capital where as a general partner he led investments in biotechnology, pharmaceuticals, and bioinformatics. He also has more than 15 years of operating experience in the biotechnology industry, with emphasis on therapeutic products, devices, diagnostics, and research instrumentation. Prior to launching his career in venture capital, Mr. Atwood was founder, president, and CEO of Glycomed, a publicly traded biotechnology company. At Glycomed, Mr. Atwood concentrated on business development and strategic alliances. Prior to this, he co-founded and served as director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer. Mr. Atwood currently serves as a Board member for Cadence Pharmaceuticals, ForteBio, Helicos Biosciences, Pharmion and Saegis Pharmaceuticals. Mr. Atwood received a Bachelor's degree in Biological Sciences from the University of California, Irvine, a Master's degree from the University of California, Davis, and an M.B.A. from Harvard Business School. | 